A Phase 3 interventional study of Lurasidone HCl in Schizophrenia and Schizoaffective Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-17.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 14th largest by enrollment, is one of 2 that started in 2010, is one of 18 in phase 3, and was the 15th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2010.
This study's enrollment of 244 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 16th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2010, is one of 21 in phase 3, and was the 16th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lurasidone HCl
Drug: Lurasidone HCl
Drug: Lurasidone HCl
Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
Also known as: Latuda
Time to Relapse of Psychotic Symptoms During 6 Weeks
Relapse is defined as any occurrence of: * Insufficient clinical response * Exacerbation of underlying disease * Discontinuation due to an adverse event
Time frame: 6 Weeks
Tolerability and Safety
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events
Time frame: 6 Weeks
FPI June 24, 2010-LPV May 19, 2011, locations were private health clinics, university hospitals, private research facilities.
| Milestone | Lurasidone Open-Label Arm 40/40 | Lurasidone Open-Label Arm 40/80 | Lurasidone Open-Label Arm 80/80 |
|---|---|---|---|
| Started | 74 | 88 | 82 |
| Completed | 58 | 73 | 67 |
| Not completed | 16 | 15 | 15 |
| Withdrew: Lack of efficacy | 0 | 2 | 1 |
| Withdrew: Adverse event | 5 | 6 | 5 |
| Withdrew: Lost to follow-up | 2 | 3 | 4 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 3 | 3 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 1 |
| Withdrew: Administrative | 1 | 0 | 0 |
| Withdrew: Principal investigator decision | 2 | 0 | 1 |
Relapse is defined as any occurrence of: * Insufficient clinical response * Exacerbation of underlying disease * Discontinuation due to an adverse event
| days | Lurasidone Open-Label Arm 40/40 | Lurasidone Open-Label Arm 40/80 | Lurasidone Open-Label Arm 80/80 |
|---|---|---|---|
| Time to Relapse of Psychotic Symptoms During 6 Weeks | 23.8 ± 12.1 | 16.9 ± 11.6 | 17.3 ± 8.9 |
Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events
| participants | Lurasidone Open-Label Arm 40/40 | Lurasidone Open-Label Arm 40/80 | Lurasidone Open-Label Arm 80/80 |
|---|---|---|---|
| Tolerability and Safety | 72 | 87 | 81 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone Open-Label Arm 40/40 | — | 3/72 (4.2%) | 45/72 (62.5%) |
| Lurasidone Open-Label Arm 40/80 | — | 2/87 (2.3%) | 62/87 (71.3%) |
| Lurasidone Open-Label Arm 80/80 | — | 0/81 (0%) | 59/81 (72.8%) |
| Event | Lurasidone Open-Label Arm 40/40 | Lurasidone Open-Label Arm 40/80 | Lurasidone Open-Label Arm 80/80 |
|---|---|---|---|
| Schizoaffective disorderPsychiatric disorders | 2/72 | 0/87 | 0/81 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/72 | 0/87 | 0/81 |
| SchizophreniaPsychiatric disorders | 1/72 | 0/87 | 0/81 |
| AlcoholismPsychiatric disorders | 0/72 | 1/87 | 0/81 |
| Sexually inappropriate behaviorPsychiatric disorders | 0/72 | 1/87 | 0/81 |
| Event | Lurasidone Open-Label Arm 40/40 | Lurasidone Open-Label Arm 40/80 | Lurasidone Open-Label Arm 80/80 |
|---|---|---|---|
| NauseaGastrointestinal disorders | 10/72 | 8/87 | 15/81 |
| InsomniaPsychiatric disorders | 3/72 | 16/87 | 12/81 |
| AkathisiaNervous system disorders | 6/72 | 13/87 | 11/81 |
| HeadacheNervous system disorders | 7/72 | 10/87 | 6/81 |
| Dry MouthGastrointestinal disorders | 3/72 | 9/87 | 2/81 |
| SomnolenceNervous system disorders | 7/72 | 7/87 | 2/81 |
| VomitingGastrointestinal disorders | 4/72 | 6/87 | 7/81 |
| AnxietyPsychiatric disorders | 2/72 | 6/87 | 1/81 |
| SedationNervous system disorders | 3/72 | 2/87 | 5/81 |
| FatigueGeneral disorders | 3/72 | 5/87 | 2/81 |
| Age, Categorical(Participants) | Lurasidone Open-Label Arm 40/40 | Lurasidone Open-Label Arm 40/80 | Lurasidone Open-Label Arm 80/80 | Total |
|---|---|---|---|---|
| <=18 years | 1 | 1 | 0 | 2 |
| Between 18 and 65 years | 71 | 85 | 81 | 237 |
| >=65 years | 0 | 1 | 0 | 1 |
| Age Continuous(years) | Lurasidone Open-Label Arm 40/40 | Lurasidone Open-Label Arm 40/80 | Lurasidone Open-Label Arm 80/80 | Total |
|---|---|---|---|---|
| Mean | 43.2 ± 11.3 | 44.0 ± 11.5 | 44.4 ± 10.0 | 43.9 ± 10.9 |
| Sex: Female, Male(Participants) | Lurasidone Open-Label Arm 40/40 | Lurasidone Open-Label Arm 40/80 | Lurasidone Open-Label Arm 80/80 | Total |
|---|---|---|---|---|
| Female | 25 | 37 | 22 | 84 |
| Male | 47 | 50 | 59 | 156 |
| Region of Enrollment(participants) | Lurasidone Open-Label Arm 40/40 | Lurasidone Open-Label Arm 40/80 | Lurasidone Open-Label Arm 80/80 | Total |
|---|---|---|---|---|
| United States | 72 | 87 | 81 | 240 |
The record gives a start of Jun 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →